Stable Angina Clinical Trial
— V-GOODOfficial title:
Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Observational Study
Verified date | June 2024 |
Source | Ministry of Health, Brazil |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The objective of this non-interventional multicentric study (NIS) is to investigate the efficacy and tolerability of treatment with Vastarel Caps LP® in symptomatic patients with angina over 3 months under conditions of daily practice. The main questions it aims to answer are data collection on antianginal efficacy, symptom class, adherence, and overall tolerability in patients treated with Vastarel Caps LP®. Patients diagnosed with chronic coronary syndrome and persistent stable angina, for whom the cardiologist chose to prescribe Trimetazidine 80mg once daily, were included in the study. Clinical information was collected in three distinct visits at baseline (V1), 1 month (V2), and 3 months (V3). During these visits, cardiologists collected the following variables based on a weekly occurrence: number of angina crises, short-acting nitrates (SAN) consumption, Canadian Cardiovascular Society (CCS) classification, level of self-reported daily physical activity, adherence, and tolerability to the treatment. Physical activity was measured using a scale from 1 to 10 (1 = no limitations, 5 = moderate limitations, and 10 = very marked limitations). Adherence was assessed by a previously validated six-item questionnaire. Assessment of therapy efficacy and tolerability were rated by the physician as "very satisfactory", "satisfactory", "not sufficiently satisfactory", and "unsatisfactory".
Status | Completed |
Enrollment | 800 |
Est. completion date | September 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients with confirmed Chronic Coronary Syndrome and persistent stable angina; - Patients who are going to start using Vastarel Caps LP® as per their doctor's recommendation. Exclusion Criteria: - Hypersensitivity to the active ingredient or any of the excipients listed in Vastarel Caps LP®; - Parkinson's disease, Parkinson's symptoms, tremors, restless leg syndrome, and other related movement disorders; - Severe renal impairment (creatinine clearance <30 mL/min); - Moderate renal impairment (creatinine clearance [30-60] mL/min). |
Country | Name | City | State |
---|---|---|---|
Brazil | InCor Heart Institute | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
Ministry of Health, Brazil | Servier |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of Vastarel Caps LP® therapy on frequency of angina episodes. | Assessment of the effect of Vastarel Caps LP® therapy on changing the number of angina attacks at 30 and 90 days, as reported by the patient. | 30 days (V2), 90 days (V3) | |
Primary | Effect of Vastarel Caps LP® therapy on the use of sublingual nitrates. | Assessment of the effect of Vastarel Caps LP® therapy on the alteration of sublingual nitrates consumption at 30 days and 90 days. | 30 days (V2), 90 days (V3) | |
Primary | Effect of Vastarel Caps LP® therapy on symptom class (CCS class). | Assessing the impact of Vastarel Caps LP® therapy on modifying symptom classification using the CCS class at 30 and 90 days. | 30 days (V2), 90 days (V3) | |
Primary | Effect of Vastarel Caps LP® therapy on daily activity. | Assessment of the impact of Vastarel Caps LP® therapy on adjusting the daily activity threshold at 30 and 90 days, utilizing the Functional Assessment Scale to be answered by the patient. | 30 days (V2), 90 days (V3) | |
Primary | Influence of Vastarel Caps LP® therapy on patient adherence. | Assessment of the impact of Vastarel Caps LP® therapy on enhancing patient adherence at 30 and 90 days, through the following questions: This morning, did you forget to take Vastarel Caps LP? Yes or No, Since our last appointment, have you taken Vastarel Caps LP after the usual time? Yes or No and Since our last appointment, have you ever forgotten to take Vastarel Caps LP? Yes or No. | 30 days (V2), 90 days (V3) | |
Secondary | Overall tolerability and adverse events (AE)/adverse drug reactions (ADR) in Vastarel Caps LP® therapy | Assessment of the effect of Vastarel Caps LP® therapy on overall patient tolerability and the occurrence of adverse events (AE)/adverse drug reactions (ADR), as reported by the patient through the following question: "How do you assess the overall tolerability of Vastarel Caps LP therapy in this patient? Very satisfactory, Satisfactory, Not satisfactory enough, or Unsatisfactory." | 30 days (V2), 90 days (V3) | |
Secondary | Overall assessment by the physician of the efficacy of Vastarel Caps LP® therapy in symptomatic patients with angina. | Assessment of the efficacy of Vastarel Caps LP® therapy based on the physician's overall evaluation through the following question: "How do you assess the overall effectiveness of Vastarel Caps LP therapy in this patient? Very satisfactory, Satisfactory, Not satisfactory enough, or Unsatisfactory." | 30 days (V2), 90 days (V3) | |
Secondary | Association of Vastarel Caps LP® efficacy according to the time since the patient's last revascularization. | Assessment of the relationship between the time elapsed since the last surgical intervention to enhance blood flow in the coronary arteries and the effectiveness of Vastarel treatment. | 30 days (V2), 90 days (V3) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Not yet recruiting |
NCT02550301 -
Does Mean Platelet Volume Change With Clopidogrel
|
N/A | |
Completed |
NCT02252406 -
Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT02244853 -
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT01162902 -
Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation
|
Phase 4 | |
Completed |
NCT01826552 -
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
|
Phase 4 | |
Completed |
NCT02126150 -
United Coronary Biobanks
|
N/A | |
Completed |
NCT01769079 -
Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina
|
Phase 4 | |
Completed |
NCT01328470 -
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
|
Phase 4 | |
Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
Completed |
NCT00263263 -
RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.
|
Phase 2 | |
Active, not recruiting |
NCT04929496 -
Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Recruiting |
NCT05459051 -
Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
|
||
Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
Completed |
NCT01974492 -
Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting
|
N/A | |
Completed |
NCT01990924 -
Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention
|
N/A | |
Completed |
NCT02120859 -
Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty
|
Phase 4 | |
Terminated |
NCT01394848 -
Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
|
Phase 4 |